Cambridge, Mass.-based startup Seventh Sense Biosystems has received $16 million in new financing from a Series B funding round. The round included new investors Novartis, Laboratory Corp. and Siemens Financial's venture capital unit, as well as previous investors Flagship Ventures and Polaris Partners. Seventh Sense Biosystems is developing a touch-activated phlebotomy system that pierces only the outer layers of the skin for blood collection that is intended to be pain-free.

Related Summaries